Host derived proteins binding HCV: medical, diagnostic and purification use
AssigneeInnogenetics N.V.
InventorsGeert Maertens, Erik Depla
Life of this patent
Estimating the term…
Abstract
The finding that the human proteins annexin V, tubulin and apolipoprotein B bind to the hepatitis C virus envelope proteins E1 and/or E2 and the usage of these human proteins to diagnose and treat an infection with hepatitis C virus are described. The usage of the latter proteins to enrich HCV envelope proteins and molecules which inhibit binding of HCV to these human proteins, as well as vaccines employing the E1 and/or E2 binding domains are also disclosed.
Claims13
A method of screening for molecules which modulate the binding between HCV and human apolipoprotein B or a functional fragment of human apolipoprotein B, comprising:
- (i) contacting an HCV E1 envelope protein or a composition comprising an HCV E1 envelope protein with said molecule, and a human apolipoprotein B or a functional fragment of a human apolipoprotein B, under conditions whereby said molecule compete with the binding of said envelope protein to said human apolipoprotein B or said functional fragment of a human apolipoprotein B;
- and
- (ii) determining the amount of HCV E1 envelope protein bound to the human apolipoprotein B or the functional fragment, whereby said amount correlates to the molecule being a modulator of the binding between HCV and the human apolipoprotein B or the functional fragment.
A method of screening for molecules which modulate the binding between HCV and human apolipoprotein B or a functional fragment of human apolipoprotein B, comprising:
- (i) contacting a predetermined amount of HCV E1 envelope protein or a composition comprising a predetermined amount of HCV E1 envelope protein with said molecule, and a human apolipoprotein B or a functional fragment of a human apolipoprotein B, under conditions whereby said molecule compete with the binding of said envelope protein to said human apolipoprotein B or said functional fragment of a human apolipoprotein B;
- and
- (ii) determining the amount of HCV E1 envelope protein bound to the human apolipoprotein B or the functional fragment, whereby said amount correlates to the molecule being a modulator of the binding between HCV and the human apolipoprotein B or the functional fragment.
A method of screening for molecules which modulated the binding between HCV and human apolipoprotein B or a functional fragment of human apolipoprotein B, comprising:
- (i) providing a complex of HCV bound to the human apolipoprotein B or the functional fragment,
- (ii) contacting a molecule suspected of being a modulator of the binding between HCV and a human apolipoprotein B or a functional fragment of human apolipoprotein B, with the complex of step (i),
- (iii) determining changes in binding in said complex, whereby a change in binding correlates to the molecule being a modulator of the binding between HCV and the human apolipoprotein B or the functional fragment.
A method of screening for molecules which modulate the binding between HCV and human apolipoprotein B or a functional fragment of human apolipoprotein B, comprising:
- (i) providing a complex of HCV from a sample of body fluid, bound to the human apolipoprotein B or the functional fragment,
- (ii) contacting a molecule suspected of being a modulator of the binding between HCV and a human apolipoprotein B or a functional fragment of human apolipoprotein B, with the complex of step (i),
- (iii) determining changes in binding in said complex, whereby a change in binding correlates to the molecule being a modulator of the binding between HCV and the human apolipoprotein B or the functional fragment.
Dependencies are inferred from the claim text.